Investor Presentaiton

ASIDS. 2023 Annual Meeting November 2-5 Chicago, IL JEUVEAU EXTRA-STRENGTH PHASE II, RANDOMIZED, DOUBLE BLIND, ACTIVE-CONTROLLED, INCREASING DOSE TRIAL STUDY: FINAL TOP LINE RESULTS DE

View entire presentation